| Literature DB >> 36004330 |
Jun Li1,2, Mengli Tang1, Zhaojun Liu1, Fengjun Xia1, Changhang Min1, Yongmei Hu1,2, Haichen Wang1,2, Mingxiang Zou1,2.
Abstract
Despite being a significant public health concern, hypervirulent Klebsiella pneumoniae (hvKP) has rarely been investigated in urinary tract infections (UTIs). To investigate the molecular and clinical characterization of hvKP in UTIs, we collected K. pneumoniae strains and clinical data from patients with UTIs. HvKP was confirmed by virulence-related genes and the Galleria mellonella model and sequenced by next-generation sequencing. Our data showed that 30/121 isolates were hvKP [17 carbapenem-resistant hypervirulent K. pneumoniae (CR-hvKP), 12 hvKP, and 1 extended-spectrum β-lactamase-producing hvKP]; these had higher resistance to most antimicrobials and were more likely to cause complicated UTIs (cUTIs). Notably, the mucoid phenotype-regulating genes prmpA and prmpA2 were truncated in 3 and 19 hvKP, respectively. Eight serotypes were detected and divided into three groups: K64 (n = 17), K1/K2 (n = 6), and others (n = 7). Furthermore, 16/17 K64 hvKP isolates were CR-hvKP but with a lower mortality rate of G. mellonella as the truncated prmpA/prmpA2 incurred high fitness cost to the isolates. In addition, all K64 isolates belonged to ST11 with the same cluster, and in two of these strains (KP88 and KP92) bla KPC-2 gene was successfully transferred to EC600. Genetic environment analysis showed that IS26-tnpR-ISKpn27-bla KPC-2-ISKpn6 may be the core structure in the horizontal transfer of bla KPC-2. The highest mortality rate among the infected G. mellonella was observed in the K1/K2 group. In conclusion, hvKP had a higher resistance rate and was more likely to lead to cUTIs. Convergence of hypervirulence and carbapenem resistance in a transmissible ST11 clone of K64 K. pneumoniae was mediated by a plasmid in UTIs. Therefore, surveillance of hvKP in UTIs should be strengthened.Entities:
Keywords: antibiotic resistance; clinical characterization; hypervirulent K. pneumoniae; urinary tract infections; whole-genome sequencing
Mesh:
Substances:
Year: 2022 PMID: 36004330 PMCID: PMC9393326 DOI: 10.3389/fcimb.2022.925440
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Clinical characteristics and susceptibility of hvKP and cKP isolates.
| hvKP ( | Non- hvKP ( |
| ||
|---|---|---|---|---|
| Age, median | 59.5 | 56.9 | 0.4676 | |
| Male sex | 17 (56.7%) | 45 (49.5%) | 0.4929 | |
| Inpatients | 21 (70.0%) | 81 (89.0%) | 0.0283 | |
|
| ||||
| Diabetes mellitus | 10 (33.3%) | 27 (29.7%) | 0.7057 | |
| Hypertension | 12 (40.0%) | 37 (40.7%) | 0.9491 | |
| Bacteremia | 22 (73.3%) | 75 (82.4%) | 0.2792 | |
| Catheter | 10 (33.3%) | 25 (27.5%) | 0.5392 | |
| Complicated UTI | 23 (76.7%) | 54 (59.3%) | 0.0871 | |
| Biofilm forming ability | 21 (70.0%) | 80 (87.9%) | 0.0447 | |
| C-reactive protein, mean ± SD | 71.62 ± 98.58 | 40.10 ± 38.31 | 0.0640 | |
| PCT, mean ± SD | 11.06 ± 39.83 | 2.22 ± 9.27 | 0.2820 | |
|
| ||||
| CRE | 17 (56.7%) | 21 (23.1%) | 0.0010 | |
| ESBLs | 1 (3.3%) | 35 (38.5%) | 0.0003 | |
| TZP | 17 (56.7%) | 20 (22.0%) | 0.0003 | |
| CAZ | 17 (56.7%) | 37 (40.7%) | 0.1261 | |
| CRO | 20 (66.7%) | 53 (58.2%) | 0.4134 | |
| FEP | 18 (60.0%) | 29 (31.9%) | 0.0061 | |
| ATM | 19 (63.3%) | 37 (40.7%) | 0.0308 | |
| IPM | 17 (56.7%) | 16 (17.6%) | 0.0000 | |
| MEM | 17 (56.7%) | 16 (17.6%) | 0.0000 | |
| AK | 15 (50.0%) | 12 (13.2%) | 0.0000 | |
| CIP | 21 (70.0%) | 66 (72.5%) | 0.7894 | |
| SXT | 11 (36.7%) | 43 (47.3%) | 0.3118 | |
| F | 23 (76.7%) | 59 (64.8%) | 0.2292 | |
| TGC | 3 (10.0%) | 15 (16.5%) | 0.5689 | |
| PB | 0 (0) | 2 (2.2%) | 1.0000 | |
| CZA | 0 (0) | 4 (4.4%) | 1.0000 | |
PCT, procalcitonin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AK, amikacin; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; F, nitrofurantoin; TGC, tigecycline; CZA, ceftazidime/avibactam; PB, polymyxin B.
Figure 1Evaluation of the virulence of KP isolates. Using a G. mellonella infection model, we investigated the virulence of 1 × 106 CFU of each KP strain (KP1, KP7, KP8, KP14, KP16, KP23, KP28, KP92, and KP110). NTUH-K2044 and ATCC 700603 were used as high- and low-virulence KP controls, respectively. The survival rates of KP7- and KP16-infected G. mellonella were similar with ATCC 700603, while those of KP1, KP8, KP14, KP23, KP28, KP92, and KP110 were similar with NTUH-K2044, indicating that they were hypervirulent.
Figure 2Molecular characterization of 30 hvKP isolates. NA, not determined. Homology analysis of 30 hvKP isolates was performed using BacWGSTdb software, and all K64 ST11 CR-hvKP strains belonged to the same cluster.
Comparison of drug resistance and virulence among K64, K1/K2 and other serotype hvKP.
| K64 ( | K1/K2 ( | Others ( | |
|---|---|---|---|
| CRE | 16 (94.1%) | 1 (16.7%) | 0 |
|
| 15 (88.2%) | 0 | 1 (14.3%) |
| Antimicrobial susceptibility | |||
| TZP | 16 (94.1%) | 1 (16.7%) | 0 |
| CAZ | 16 (94.1%) | 1 (16.7%) | 0 |
| CRO | 17 (100.0%) | 2 (33.3%) | 2 (28.6%) |
| FEP | 17 (100.0%) | 1 (16.7%) | 0 |
| ATM | 17 (100.0%) | 1 (16.7%) | 1 (14.3%) |
| IPM | 16 (94.1%) | 1 (16.7%) | 0 |
| MEM | 16 (94.1%) | 1 (16.7%) | 0 |
| AK | 14 (82.4%) | 1 (16.7%) | 0 |
| GEN | 14 (82.4%) | 1 (16.7%) | 0 |
| CIP | 17 (100.0%) | 3 (50.0%) | 1 (14.3%) |
| LEV | 17 (100.0%) | 1 (16.7%) | 0 |
| SXT | 11 (64.7%) | 0 | 0 |
| F | 17 (100.0%) | 4 (66.7%) | 2 (28.6%) |
| mortality rate of | 56.0% | 70.0% | 62.0% |
|
| 7 (41.2%) | 6 (100.0%) | 5 (71.4%) |
|
| 16 (94.1%) | 1 (16.7%) | 3 (42.9%) |
TZP, piperacillin/tazobactam; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; F, nitrofurantoin.
Susceptibility of KP88, KP88*, KP92, KP92*, and EC600.
| Strains | MIC (μg/mL) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TZP | CAZ | FEP | ATM | IPM | MEM | AK | LEV | F | CZA | TGC | PB | |
| KP88 | >512/4 | 64 | >128 | >128 | >32 | >32 | ≤4 | >16 | 512 | ≤1/4 | 0.5 | 0.5 |
| KP88* | >512/4 | 8 | 8 | 128 | 8 | 8 | ≤4 | 2 | 8 | ≤1/4 | 0.25 | ≤0.25 |
| KP92 | >512/4 | >128 | >128 | >128 | >32 | >32 | >512 | >16 | 256 | 2/4 | 0.25 | 0.5 |
| KP92* | 512/4 | 128 | 32 | >128 | 16 | 4 | >512 | 2 | ≤4 | ≤1/4 | ≤0.125 | 0.5 |
| EC600 | 2 | ≤1 | ≤1 | ≤1 | ≤0.25 | ≤0.25 | ≤4 | ≤0.125 | 8 | ≤1/4 | ≤0.125 | 0.25 |
KP88*, KP92*, Transconjugants; TZP, piperacillin/tazobactam; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; AK, amikacin; LEV, levofloxacin; F, nitrofurantoin; CZA, ceftazidime/avibactam; TGC, tigecycline; PB, polymyxin B.
Genome characteristics of isolate KP92.
| Genetic context | Length (bp) | Plasmid type | Acquired antimicrobial resistance genes | Virulence genes |
|---|---|---|---|---|
| Chromosome | 5,392,339 | – |
|
|
| Plasmid 1 | 144,551 | IncFII (pHN7A8) |
| – |
| Plasmid 2 | 216,439 | IncFIB (K) (pCAV1099-114) | – |
|
| Plasmid 3 | 47,106 | IncN |
| – |
-: not detected.